Browning JC, Cartwright M, Thorla, Jr. I, Martin SA, Olayinka-Amao O, Maeda-Chubachi T. A patient-centered perspective of molluscum contagiosum as reported by B-SIMPLE4 clinical trial patients and caregivers: global impression of change and exit interview substudy results. Am J Clin Dermatol. 2023 Jan;24(1):119-33. doi: 10.1007/s40257-022-00733-9
Hollis K, Proctor C, McBride D, Balp MM, McLeod L, Hunter S, Tian H, Khalil S, Maurer M. Comparison of Urticaria Activity Score over 7 days (UAS7) values obtained from once-daily and twice daily versions: results from the ASSURE-CSU study. Am J Clin Dermatol. 2018 Apr;19(2):267-74. doi: 10.1007/s40257-017-0331-8
Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;129(36). doi: 10.1179/1607845414Y.0000000179
Edwards T, Cadigan RJ, Evans JP, Henderson GE. Biobanks containing clinical specimens: defining characteristics, policies, and practices. Clin Biochem. 2014 Mar;47(4-5):245-51. doi: 10.1016/j.clinbiochem.2013.11.023
Earnshaw SR, Wilson M, Joshi AV. The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface. 2007 Jan 1;19(11):39-45.
Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.
Earnshaw SR, Candrilli SD, Fernandes AW, Higashi MK. A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia. Managed Care Interface. 2005 Oct 1;18(10):36-44.
Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003 Feb 1;4(2):131-9.